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DProper anchoring of the balloon-expandable valve within
the sewing ring of the mitral prosthesis ensured stability
and minimized paravalvular leakage.
The hemodynamic results ofmitral TVIViwere acceptable,
with a residual median gradient of 7.5 mmHg. The transvalv-
ular gradient improved significantly in the 3 patients with
severe stenosis. The residual gradient of 8 mm Hg is not
much different from that seen with the available mitral
bioprostheses. In addition, most of our patients had valvular
insufficiency, and there was no significant valvular or para-
valvular insufficiency in our cohort. All patients had dramatic
improvement in their symptoms and remained inNYHA class
I/II at last follow-up. No structural deterioration was demon-
strated in our relatively short follow-up. Like other biological
prosthesis, these valve stents can be expected to fail in the
future. However, the mode of failure and the long-term
durability of these valve stents remains unknown.
In our limited study, there was no operative mortality, and
86% of our high-risk elderly patients were alive and well at
last follow-up.
CONCLUSIONS
Transapical mitral TVIVi is a feasible and reproducible
procedure. Our early experience with this strategy is encour-
aging. In patients with high or prohibitive risk for reoperative
mitral valve surgery, transapical TVIVi should be considered
as an option.
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Dr Noboru Motomura (Tokyo, Japan). Thank you very much.
I enjoyed it. Just a few quick questions. One is can you do this
procedure again and again like Sapien, in Sapien procedure, in
the future? Second question is, is there any technical difficulty
when the posterior leaflet preservation had been done in the
first-time operation in AVR? Thank you.
Dr Cheung. For your first question, I am Chinese but I am not
a fortune teller; however, I do think that with the low transvalvular
gradient that we have observed with the valve-in-valve procedures,
I think it is possible to perform a second or third transcatheter
valve-in-valve procedure.
The second question was?
Dr Acker.When you leave the subvalvular apparatus, does that
pose a technical challenge?
Dr Cheung. For the second question, 3 of our 8 patients with
previous mitral valve replacement had anterior and posterior leaf-
let preservation. We had no problem accessing mitral prosthesis.
No problem with any guide wire getting caught on any subvalvular
apparatus.
Dr Kristopher Kallin (Los Angeles, Calif). Just a quick ques-
tion about visualizing where you are going to place the valve. Was
this performed in a hybrid type of cardiac OR or were you using
a C-arm?
Dr Cheung. All operations were performed in the hybrid OR
with full catheter lab imaging capability. The placement of the
valve is actually most accurately guided by echocardiography.
Many mitral prostheses do not have radiolucent markers to guide
the implant. Basically, it is best to land the Spaien valve about 3
to 5 mm on the atrial side at the sewing ring and will provide
the best anchorage.rdiovascular Surgery c Volume 141, Number 3 715
